Not too big, not too small: A goldilocks approach to sample size selection

Journal of Biopharmaceutical Statistics

Volumn 24, Issue 3, 2014, Pages 685-705

  Broglio, Kristine R ^a   Connor, Jason T ^a,b   Berry, Scott M ^a  

^a BERRY CONSULTANTS   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA   (United States)

Author keywords

Bayesian adaptive trial design; Predictive probabilities; Sample size; Sequential design.

Indexed keywords

ALGORITHM; ARTICLE; BAYES THEOREM; FOLLOW UP; HUMAN; LYMPH NODE; ONCOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROBABILITY; SAMPLE SIZE; BINOMIAL DISTRIBUTION; BIOASSAY; BREAST TUMOR; FEMALE; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENTINEL LYMPH NODE BIOPSY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; SURVIVAL;

ALGORITHMS; BAYES THEOREM; BINOMIAL DISTRIBUTION; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; ENDPOINT DETERMINATION; FEMALE; HUMANS; LYMPH NODES; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE; SENTINEL LYMPH NODE BIOPSY; SURVIVAL ANALYSIS;

EID: 84899013925     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2014.888569     Document Type: Article

References (21)

1. AtriCure. (n.d.). AtriCure bipolar radiofrequency ablation of permanent atrial fibrillation (ABLATE). http://clinicaltrials.gov/ct2/show/NCT00560885 (accessed November 20, 2012).
2. Berry, D. A. (1989). Monitoring accumulating data in a clinical trial. Biometrics 45(4):1197-1211.
3. Berry, D. A. (2004). Bayesian statistics and the efficiency and ethics of clinical trials. StatisticalScience 19(1):175-187.
4. Choi, S. C., Pepple, P. A. (1989). Monitoring clinical trials based on predictive probability ofsignificance. Biometrics 45(1):317-323.
5. Dmitrienko, A., Wang, M.-D. (2006). Bayesian predictive approach to interim monitoring in clinicaltrials. Statistics in Medicine 25(13):2178-2195.
6. Food and Drug Administration.(2010). Guidance for industry adaptive design clinical trials fordrugs and biologics. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm201790.pdf
7. Gaydos, B., Anderson, K. M., Berry, D., Burnham, N., Chuang-Stein, C., Dudinak, J., Fardipour, P.,et al. (2009). Good practices for adaptive clinical trials in pharmaceutical product development. Drug Information Journal 43(5):539-556.
8. Gelman, A, Carlin, J. B., Stern, H. S., Rubin, D. B. (2003). Bayesian Data Analysis, 2nd ed. BocaRaton, FL: Chapman and Hall/CRC.
9. Hampson, L. V. and Jennison, C. (2013). Group sequential tests for delayed responses (withdiscussion). Journal of the Royal Statistical Society, Series B 75(1):3-54.
10. He, W., Kuznetsova, O. M., Harmer, M., Leahy, C., Anderson, K., Dossin, N., Li, L., Bolognese,J., Tymofyeyev, Y., Schindler, J. (2012). Practical considerations and strategies for executingadaptive clinical trials. Drug Information Journal 46(2):160-174.
11. Herson J. (1979). Predictive probability early termination plans for Phase II clinical trials. Biometrics35:775-783.
12. Julian, T. B., Blumencranz, P., Deck, K., Whitworth, P., Berry, D. A., Berry, S. M., Rosenberg, A., etal. (2008). Novel intraoperative molecular test for sentinel lymph node metastases in patientswith early-stage breast cancer. Journal of Clinical Oncology: Official Journal of the AmericanSociety of Clinical Oncology 26(20):3338-3345.
13. Kelly, C. M., Green, M. C., Broglio, K., Thomas, E. S., Brewster, A. M., Valero, V., Ibrahim, N. K.,et al. (2012). Phase III trial evaluating weekly paclitaxel versus docetaxel in combination withcapecitabine in operable breast cancer. Journal of Clinical Oncology 30(9): 930-935.
14. Muss, H. B., Berry, D. A., Cirrincione, C. T., Theodoulou, M., Mauer, A. M., Kornblith, A. B.,Partridge, A. H., et al. (2009). Adjuvant chemotherapy in older women with early-stage breastcancer. New England Journal of Medicine 360(20):2055-2065.
15. Oncolytics Biotech. (n.d.). Efficacy study of REOLYSIN® in combination with paclitaxel andcarboplatin in platinum-refractory head and neck cancers. http://clinicaltrials.gov/ct2/show/NCT00560885 (accessed November 19, 2012).
16. Patient-Centered Outcomes Research Institute. (2012). Draft Methodology Report: "Our Questions,Our Decisions: Standards for Patient-centered Outcomes Research." Draft. Patient-Centered Outcomes Research Institute. http://pcori.org/assets/MethodologyReport-Comment.pdf (accessed September 20, 2012).
17. R Development Core Team. (2011). R: A Language and Environment for Statistical Computing. RFoundation for Statistical Computing, Vienna, Austria. http://www.R-project.org
18. Saville, B. R., Connor, J. T., Ayers, G. D., Alvarez, J. (in press). The utility of Bayesian predictiveprobabilities for interim monitoring of clinical trials. Clinical Trials.
19. Spiegelhalter, D. J., Freedman, L. S., Blackburn, P. R. (1986). Monitoring clinical trials: Conditionalor predictive power? Controlled Clinical Trials 7:8-17.
20. White, W. B., Grady, D., Giudice, L. C., Berry, S. M., Zborowski, J., Snabes, M. C. (2012). Acardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women withelevated cardiovascular risk and hypoactive sexual desire disorder. American Heart Journal163(1):27-32.
21. Wilber, D. J., Pappone, C., Neuzil, P., De Paola, A., Marchlinski, F., Natale, A., Macle, L., Daoud,E. G., Calkins, H., Hall, B., Reddy, V., Augello, G., Reynolds, M. R., Vinekar, C., Liu, C. Y.,Berry, S. M., Berry, D. A., for the ThermoCool AF Trial Investigators. (2010). Comparison ofantiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmalatrial fibrillation: A randomized controlled trial. Journal of the American Medical Association303(4):333-340.